PFIZER2024-04-012024-06-30 PFIZER2024-04-012024-06-30in-bse-fin:OneOperatingExpenses01Member PFIZER2024-06-30 PFIZER2024-04-012024-06-30in-bse-fin:OneItemsThatWillNotBeReclassifiedToProfitAndLoss01Member iso4217:INRxbrli:purexbrli:sharesiso4217:INRxbrli:shares 500680 PFIZER NA Pfizer Limited Equity 2024-04-01 2025-03-31 2024-07-29 2024-07-22 INR Crores First quarter 16:00:00 19:25:00 2024-07-29 2024-07-29 Not applicable Single segment Pharmaceuticals 2024-04-01 2024-06-30 Unaudited Standalone 5628600000.00 418400000.00 6047000000.00 577400000.00 1875900000.00 -446400000.00 913700000.00 21100000.00 146000000.00 933100000.00 4020800000.00 2026200000.00 0.00 2026200000.00 550500000.00 -31400000.00 519100000.00 0.00 1507100000.00 0.00 0.00 0.00 0.00 1507100000.00 -5400000.00 1501700000.00 0.00 0.00 457500000.00 10 32.94 32.94 0.00 0.00 32.94 32.94 0.00 0.00 0.00 1.The above financial results were reviewed by the Audit Committee, and thereafter approved by the Board of Directors at their meeting held on July 29, 2024. 2.The financial results of the Company have been prepared in accordance with Indian Accounting Standards (‘Ind AS”) prescribed under Section 133 of the Companies Act, 2013 read with relevant rules thereunder and in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended from time to time). 3.The financial results for the quarter ended June 30, 2024 have been subject to limited review by the statutory auditors of the Company. The limited review report does not contain any modifications. The limited review report will be filed with the Stock Exchanges and will also be available on the Company’s website - www.pfizerltd.co.in 4.Figures for the quarter ended March 31, 2024 represent the difference between the audited figures in respect of the full financial year and published figures of nine months ended December 31, 2023 which were subject to a limited review by the statutory auditors. 5.Exceptional item for the year ended March 31, 2024 is in relation to provision for old pending VAT / CST litigations. The Company opted for Maharashtra VAT Amnesty Scheme for certain years and had received final settlement orders. Pursuant to the said orders the Company had written back excess provision of Rs.7.95 crore. 6.The Company has only one segment which is ‘Pharmaceuticals’. Therefore disclosure relating to segments is not applicable and accordingly not made. Other Expenses 933100000.00 Items that will not be reclassified subsequently to profit and loss -7200000.00 -7200000.00 -1800000.00 0.00